Gut microbiome clusters may help predict inflammatory bowel disease severity and progression
Peer-Reviewed Publication
Updates every hour. Last Updated: 1-Jun-2026 16:16 ET (1-Jun-2026 20:16 GMT/UTC)
A new study published in Microbiome Research Reports shows that patients with inflammatory bowel disease (IBD) can be stratified into distinct gut microbiome “cluster types” associated with differences in disease severity and progression risk. Rather than individual bacterial taxa, the study highlights community-level microbial structures as more robust indicators of disease heterogeneity. These microbiome-derived clusters were independent of traditional clinical classifications such as Crohn’s disease and ulcerative colitis, suggesting that gut ecosystem organization may offer complementary insights for disease assessment and future precision medicine.
Researchers at Nanjing University developed platinum(IV)-antibody conjugates that enhance tumor immunogenicity without relying on strong cancer cell killing. The targeted system delivers low-dose platinum selectively to tumors, increasing MHC-I expression and improving immune recognition while reducing systemic toxicity. In mouse models, the strategy significantly enhanced the efficacy of anti-PD-1 immunotherapy.
When evaluating the health of native, wild snakes in the southeastern US, some species emerged as particularly sickly, a new study showed. Pygmy rattlesnakes – historically persecuted by humans – were found to be particularly affected by disease caused by fungi and parasites. The study also showed that other factors such as location and simultaneous infections can influence snake health, too. The team said this broad overview of native snakes’ health could help prevent pathogen spillover between native and invasive as well as free-living and captive snakes.
Researchers from The University of Osaka have found that the rat brain differs from other mammals in the proportion of upper and deep layer neurons in the cortex. This change likely arises from differences in the timing of signaling pathways during early brain development. Importantly, this identified mechanism may have future applications in regenerative medicine for developmental and neurological disorders.
This four-paper Series and accompanying comments examine the growing but under-recognised burden of chronic liver disease in Europe, with a focus on steatotic liver disease, including metabolic dysfunction-associated steatotic liver disease, and alcohol-related liver disease, along with viral hepatitis B and C. The Series provides country-level data on MASLD policies, analyses systemic failures in prevention, timely detection, and equitable access to care across diverse populations and health systems; and evaluates policy gaps, health system responses, and innovations in diagnostics, care models, and public health strategies. The Series calls for the rapid integration of metabolic liver health into non-communicable disease frameworks, strengthened surveillance and care pathways, and coordinated, equity-driven, and preventative approaches to identify the “missing millions” and reduce the rising human and economic toll of chronic liver disease across the region.